Table 2 Immunologic details before and after desensitization
Variables | CDC − FC+ (n = 39) | CDC + FC+ (n = 17) |
|---|---|---|
FC positivity, % (B / T and B) | 53.9 / 46.1 | – |
FC MFI ratio | ||
 T cell positive (n = 21), median (IQR) | 3.6 (2.9–6.8) Max 18.3 | – |
 B cell positive (n = 39), median (IQR) | 8.0 (4.4–17.4) Max 53.3 | – |
CDC positivity, % (B / T and B) | – | 64.7 / 35.3 |
CDC titer | ||
 T cell (AHG phase), number (1:2 / 1:4 / 1:8 / 1:32) | – | 2 / 1 / 2 / 1 |
 B cell (Warm phase), number (1:1 / 1:2 / 1:4 / 1:32) | – | 3 / 6 / 7 / 1 |
 Number of Pretransplant PP + IVIG, median (IQR) | 3 (3–4) Max 8 | 6 (4–7) Max 11 |
Pre-desensitization DSA | ||
 HLA Class, % (I / II / I + II) | 17.9 / 53.8 / 28.3 | 17.6 / 35.3 / 47.1 |
 Number, median (IQR) | 2 (1–3) | 5 (5–6) |
 Immunodominant DSA, % (A / B / DR / DQ) | 12.8 / 15.4 / 56.4 / 15.4 | 11.9 / 17.6/ 52.9 / 17.6 |
 Immunodominant MFI, median (IQR) | 4219 (2357–10000) Max 12802 | 10951 (5732–14724) Max 18056 |
 Sum of MFI, median (IQR) | 6577 (3686–13580) Max 45735 | 14663 (7818–24202) Max 66434 |
 Positive for C1q binding assay | Not examined | 9 of 16, not examined in 1 |
Post-desensitization DSA | ||
 HLA Class, % (None / I / II / I + II) | 30.8 / 12.8 / 46.2 / 10.3 | 11.8 / 23.5 / 41.2 / 23.5 |
 Number, median (IQR) | 1 (0–2) | 2 (1–3) |
 Immunodominant DSA, % (None/A / B / DR / DQ) | 30.8 / 7.7 / 10.3 / 41.0 / 10.2 | 11.8 / 11.8 / 11.8 / 52.8 / 11.8 |
 Immunodominant MFI, median (IQR) | 1902 (0–4294) Max 11979 | 4379 (1492–10457) Max 19235 |
 Sum of MFI, median (IQR) | 2685 (0–5811) Max 32811 | 5250 (2264–15,844) Max 36252 |
 Positive for C1q binding assay | Not examined | 0 of 16, not examined in 1 |